Monitoring of asymptomatic AIP mutated PituitarY patients ( MAAPY ): An ENEA study
Journal of Neuroendocrinology · 2026-11 · 38 (11)
DOI: 10.1111/jne.70338 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 16.11.2026. Verfasst von Cécilia Piazzola und 29 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Université, INSERM, MMG, MarMaRa Institute, UMR 1251, APHM, La Conception University Hospital, Department of Endocrinology, Marseille, …. Hauptthemen laut MEDLINE: Adenoma, Intracellular Signaling Peptides and Proteins, Pituitary Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aix Marseille Université, European Neuro-Endocrine Association, Assistance Publique des Hôpitaux de Marseille (APHM).
Abstract (Originalsprache)
The penetrance of pathogenic‐likely pathogenic (PV‐LPV) AIP variants is incomplete, as only 15%–30% of carriers develop a pituitary adenoma. There is no clear consensus on the optimal follow‐up for relatives carrying an AIP pathogenic variant. The Monitoring of Asymptomatic AIP mutated PituitarY patients (MAAPY) study, initiated by the European NeuroEndocrine Association, aims to recruit family members of patients with a pathogenic AIP variant to assess the risk of asymptomatic AIP mutation carriers developing pituitary adenomas and to suggest the optimal follow‐up for these individuals. This retrospective study invited endocrinologists worldwide to contribute. Index cases with AIP variants who developed a pituitary adenoma were included, as well as their relatives, whether affected or asymptomatic. Each variant was reclassified according to the ACMG‐AMP guidelines to assess pathogenicity. A total of 19 centers from 5 countries contributed data and included 209 subjects with 55 different AIP variants. Of these, 39 were classified as PV‐LPV variants and involved 167 individuals: 62 index cases and 105 relatives from 38 different kindreds. No relatives were tested for 24 index cases. Among relatives carrying PV‐LPV, 23 were affected and 82 were asymptomatic. Index cases were significantly younger at PitNET diagnosis compared to affected relatives (median 20.0 ± 9.1 vs. 30.2 ± 10.1 years, respectively; p < .0002), while index cases presented more frequently with macroadenomas compared with affected relatives (96.6% vs. 75.0%). In all but one of the affected relatives, the PitNET was already known at the time of the molecular diagnosis or was diagnosed during the initial assessment following genetic testing. One asymptomatic patient diagnosed genetically at age 18 subsequently developed a somatotroph microadenoma at the age of 27. The maximum estimated cumulative incidence among relatives carrying PV‐LPV was 28% by age 49. The median age at molecular diagnosis in asymptomatic relatives was 38 years, with limited follow‐up after genetic testing. This retrospective study shows a penetrance of AIP PV‐LPV of 28% after variant reclassification. When genetic screening is performed after the age of 30, the PitNET is already known or diagnosed during the initial assessment following genetic testing. Our data suggest that long‐term follow‐up has a low yield and may be unnecessary thereafter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille Université, INSERM, MMG, MarMaRa Institute, UMR 1251, APHM, La Conception University Hospital, Department of Endocrinology, Marseille, France.
- Aix Marseille Université, INSERM, MMG, UMR 1251, APHM, La Timone University Hospital, Laboratory of Molecular Biology GEnOPé, Marseille, France.
- Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.
- Department of Endocrinology and Metabolic Diseases, CHU Larrey, Toulouse, France.
- Department of Endocrinology Diabetology, University of Reims, Reims, France.
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Bordeaux, Bordeaux, France.
ORCID-Profile: Cécilia Piazzola, Pauline Romanet, Adrian Daly, Brigitte Delemer, Luciana Naves, Marie-Lise Jaffrain-Rea, Nicolas Sahakian, Martha Korbonits, Albert Beckers, Frédéric Castinetti, Thierry Brue
Förderung
- Aix Marseille Université
- European Neuro-Endocrine Association
- Assistance Publique des Hôpitaux de Marseille (APHM)
Zitieren
APA
Piazzola, C., Romanet, P., Daly, A., Vezzosi, D., Delemer, B., Tabarin, A., Raingeard, I., Kerlan, V., Fedala, S., Salle, L., Vaduva, P., Merlen, É., Teissier, R., Ferriere, A., Naves, L., Rosa, I. N., Jaffrain-Rea, M. L., Sabaté, M. I., Guitelman, M., …, & Barlier, A. (2026). Monitoring of asymptomatic AIP mutated PituitarY patients ( MAAPY ): An ENEA study. Journal of Neuroendocrinology, 38(11). https://doi.org/10.1111/jne.70338
Vancouver
Piazzola C, Romanet P, Daly A, Vezzosi D, Delemer B, Tabarin A, et al. Monitoring of asymptomatic AIP mutated PituitarY patients ( MAAPY ): An ENEA study. Journal of Neuroendocrinology. 2026;38(11). doi:10.1111/jne.70338
BibTeX
@article{Piazzola2026,
author = {Piazzola, Cécilia and Romanet, Pauline and Daly, Adrian and Vezzosi, Delphine and Delemer, Brigitte and Tabarin, Antoine and Raingeard, Isabelle and Kerlan, Véronique and Fedala, Saida and Salle, Laurence and Vaduva, Patricia and Merlen, Émilie and Teissier, Raphael and Ferriere, Amandine and Naves, Luciana and Rosa, Isabella Naves and Jaffrain-Rea, Marie-Lise and Sabaté, Maria Isabel and Guitelman, Mirtha and Pétrossians, Patrick and Sahakian, Nicolas and Charnay, Théo and Le Bars, Florence Pihan and Reynaud, Rachel and Rodien, Patrice and Korbonits, Martha and Beckers, Albert and Castinetti, Frédéric and Brue, Thierry and Barlier, Anne},
title = {Monitoring of asymptomatic AIP mutated PituitarY patients ( MAAPY ): An ENEA study},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {11},
doi = {10.1111/jne.70338}
}
EUVIMED